• About
    • Login
    View Item 
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Harnessing RIG-I in the tumor microenvironment for therapeutic breast cancer treatment

    Elion, David Len
    : https://etd.library.vanderbilt.edu/etd-11132019-155646
    http://hdl.handle.net/1803/14516
    : 2019-11-14

    Abstract

    RIG-I is a cytoplasmic RNA helicase expressed in most cells of the body, functioning to sense viral oligonucleotide motifs then activate innate immune responses to combat viral infection. RIG-I expression and activity is retained in most cancer cells and cells of the tumor microenvironment (TME). These observations support a growing research interest in potential use of synthetic RIG-I agonists in cancer therapy. Using an engineered RIG-I agonist, SLR20, we tested the applicability of therapeutic RIG-I activation in breast cancer. SLR20 treatment triggered the extrinsic apoptosis and pyroptosis cell death pathways in breast cancer cells. SLR20 treatment, in vivo, increased tumor infiltrating lymphocytes and decreased mammary tumor growth and metastasis. T-cell activation and tumor cell killing was increased upon co-culture of T-cells with SLR20-treated breast cancer cells, and dual immunization of wild-type mice with SLR20 and 4T1 cancer cell lysates reduced future tumor growth. Overall, these findings demonstrate hat RIG-I agonist have the capacity to induce tumor cell killing and modulate the tumor microenvironment in vivo. These reports indicate that therapeutic RIG-I signaling operates at the interface of innate and adaptive immunity within breast tumors to redirect T-cell responses in the TME.
    Show full item record

    Files in this item

    Icon
    Name:
    Elion.pdf
    Size:
    4.508Mb
    Format:
    PDF
    View/Open

    This item appears in the following collection(s):

    • Electronic Theses and Dissertations

    Connect with Vanderbilt Libraries

    Your Vanderbilt

    • Alumni
    • Current Students
    • Faculty & Staff
    • International Students
    • Media
    • Parents & Family
    • Prospective Students
    • Researchers
    • Sports Fans
    • Visitors & Neighbors

    Support the Jean and Alexander Heard Libraries

    Support the Library...Give Now

    Gifts to the Libraries support the learning and research needs of the entire Vanderbilt community. Learn more about giving to the Libraries.

    Become a Friend of the Libraries

    Quick Links

    • Hours
    • About
    • Employment
    • Staff Directory
    • Accessibility Services
    • Contact
    • Vanderbilt Home
    • Privacy Policy